Studies in patients with PCOS and obesity treated with MTF have shown that, at the endometrial level, the use of MTF increases the phosphorylation of AMPK and, consequently, the transcription factor MEF2A, thus regulating the expression of GLUT4 by increasing the transcription and translation of this transporter [17]. This evidence concerns the gene SLC2A4 and obesity disorder.